Premature ejaculation: A review

Gajjala, Sukumar Reddy; Khalidi, Azheel

doi:10.4103/0253-7184.142391

Cited by 10 publications

(8 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a normal condition, these events occur reflexively, and require coordination of autonomic and somatic nervous system in order to achieve effective delivery of semen (Grillner 1985 ; Giuliano & Clement 2005 ; Yonezawa et al. 2009 ; Gajjala & Khalidi 2014 ; Huang et al. 2016 ; Kozyrev et al.…”

Section: Discussionmentioning

confidence: 99%

Guibourtia tessmannii -induced fictive ejaculation in spinal male rat: involvement of D ₁ , D ₂ -like receptors

Defo

Asongu

Wankeu

et al. 2017

Pharmaceutical Biology

View full text Add to dashboard Cite

Context:Guibourtia tessmannii (Caesalpiniaceae) is a plant traditionally used as aphrodisiac. We previously reported the pro-ejaculatory effects of the aqueous and methanol extracts of G. tesmannii in spinal male rat. However, the mechanism underlying such effects has not been elucidated.Objective: This study characterizes the dopaminergic sub-type receptors involved in G. tesmannii-induced ejaculation in male Wistar rat.Materials and methods: Urethane-anesthetized spinal male rats were intravenously treated with saline solution (1 mL/kg, control); dopamine (0.1 μmol/kg, reference); aqueous or methanol extracts of G. tesmannii (20 mg/kg) in the absence or presence of haloperidol (0.26 μmol/kg), a nonspecific dopaminergic receptor antagonist, Sch23390 (0.26 μmol/kg), a specific D1-like receptor antagonist or, sulpiride (0.26 μmol/kg), a specific D2-like receptor antagonist. Electromyography of the bulbospongiosus muscles and intraseminal pressure were recorded after urethral, penile and drug stimulations.Results: Urethral and penile stimulations, intravenous injection of dopamine or, aqueous and methanol extracts of G. tesmannii always triggered the expression of rhythmic contraction of the bulbospongiosus muscles with an average mean of 3.33 ± 0.43; 7.83 ± 0.85; 9.80 ± 0.86; 0.83 ± 0.54 and 2.67 ± 0.95 contractions, respectively. The intraseminal pressure was more expressed after urethral and penile stimulations (15.66 ± 1.58 and 13.60 ± 2.40 mmHg, respectively). In rats pretreated with haloperidol, Sch23390 or sulpiride, no ejaculation was recorded after intravenous injection of G. tesmannii extracts or dopamine.Discussion and conclusion:Guibourtia tesmannii-induced ejaculation requires the integrity of D1 and D2-like receptors. These findings further justify the ethno-medicinal claims of G. tesmannii as an aphrodisiac.

show abstract

Section: Discussionmentioning

confidence: 99%

Guibourtia tessmannii -induced fictive ejaculation in spinal male rat: involvement of D ₁ , D ₂ -like receptors

Defo

Asongu

Wankeu

et al. 2017

Pharmaceutical Biology

View full text Add to dashboard Cite

show abstract

“…As alternatives, topical agents can be applied to reduce penile sensitivity. These include anesthetic agents and preservatives based on lidocaine and prilocaine, which act locally, with minimal systemic effects, or at most the slight possibility of allergic reactions ( Batista et al, 2021 ; Butcher et al, 2020 ; Gajjala & Khalidi, 2014 ).…”

Section: Introductionmentioning

confidence: 99%

Clinical Safety of a Pharmaceutical Formulation Containing an Extract of Acmella oleracea (L.) in Patients With Premature Ejaculation: A Pilot Study

et al. 2023

View full text Add to dashboard Cite

Acmella oleracea (L.) R. K. Jansen (Asteraceae) is a plant species widely used in traditional Amazonian medicine to treat sexual dysfunction. The use of this plant has gained popularity because of its sensory properties, such as a tingling sensation. In this study on patients with premature ejaculation, we evaluated the clinical action of a nano-formulation containing an ethanolic extract of A. oleracea inflorescences. Major constituents in the extracts were identified based on gas chromatographic analysis. Participants used a spray preparation based on the A. oleracea extract for 12 weeks, during which they were instructed to apply the product 5 min prior to sexual intercourse. To assess therapeutic efficacy, participants were required to record the mean intravaginal latency time for ejaculation (IELT). During the period of spray treatment, the nano-formulation of A. oleracea increased participant IELT values ( M = 293 s) compared with the baseline values (193 s). This nano-formulation reported clinical action in patients with premature ejaculation. It is accordingly considered to have potential application as a therapeutic alternative with benefits for both patients and their partners. Given the small number of participants in this study, further multicenter studies involving a larger number of participants are needed to confirm these observations.

show abstract

“…PE is categorised as a sexual disorder in the Diagnostic and Statistical Manual of Mental Disorders‐5 (DSM‐5) and is defined as follows: “the experience of a pattern of ejaculation occurring during partnered sexual activity within 1 min after vaginal penetration and before the individual wishes it, which persists for at least 6 months and cannot be explained by other medical causes” (Arlington, ). There are four subtypes of PE: primary (lifelong), secondary (acquired), variable and subjective (Gajjala & Khalidi, ). Primary and secondary PE are both characterised by consistently occurring premature ejaculation, but, while primary PE has been present since the patient's first sexual experiences, secondary PE develops at some point further in life.…”

Section: Introductionmentioning

confidence: 99%

Is testosterone replacement an effective treatment of secondary premature ejaculation?

Tahtali

2019

Andrologia

View full text Add to dashboard Cite

There are very few studies that have evaluated premature ejaculation characteristics in regard to subtypes. Additionally, to our knowledge, there are no studies which have explored testosterone replacement therapy in secondary premature ejaculation patients with testosterone deficiency. Therefore, our aims were as follows: (a) to determine the characteristics of patients with premature ejaculation in regard to the four subtypes of premature ejaculation and (b) to determine the efficacy of testosterone replacement therapy in the treatment of testosterone-deficient patients with secondary premature ejaculation. Patients who applied to our clinic from May 2010to August 2018 with premature ejaculation were included in this study. The mean age of the study group was 36.42 (min-max: 24-52) years. Those with secondary premature ejaculation were found to have significantly lower testosterone concentration compared to the other groups. Shortest mean intravaginal ejaculation latency time and lowest International Index of Erectile Function-5 score were found among those with secondary PE. In regard to treatment results, recipients of testosterone replacement demonstrated a 4.8-fold increase in mean intravaginal ejaculation latency time, while dapoxetine recipients had a 1.8-fold increase. Our findings demonstrate that testosterone replacement may be a promising treatment for those with secondary PE in the presence of testosterone deficiency.

show abstract

Premature ejaculation: A review

Cited by 10 publications

References 25 publications

Guibourtia tessmannii -induced fictive ejaculation in spinal male rat: involvement of D ₁ , D ₂ -like receptors

Guibourtia tessmannii -induced fictive ejaculation in spinal male rat: involvement of D ₁ , D ₂ -like receptors

Clinical Safety of a Pharmaceutical Formulation Containing an Extract of Acmella oleracea (L.) in Patients With Premature Ejaculation: A Pilot Study

Is testosterone replacement an effective treatment of secondary premature ejaculation?

Contact Info

Product

Resources

About

Premature ejaculation: A review

Cited by 10 publications

References 25 publications

Guibourtia tessmannii -induced fictive ejaculation in spinal male rat: involvement of D 1 , D 2 -like receptors

Guibourtia tessmannii -induced fictive ejaculation in spinal male rat: involvement of D 1 , D 2 -like receptors

Clinical Safety of a Pharmaceutical Formulation Containing an Extract of Acmella oleracea (L.) in Patients With Premature Ejaculation: A Pilot Study

Is testosterone replacement an effective treatment of secondary premature ejaculation?

Contact Info

Product

Resources

About

Guibourtia tessmannii -induced fictive ejaculation in spinal male rat: involvement of D ₁ , D ₂ -like receptors

Guibourtia tessmannii -induced fictive ejaculation in spinal male rat: involvement of D ₁ , D ₂ -like receptors